KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Revenue (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Revenue for 15 consecutive years, with $211.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 21.48% to $211.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $719.0 million, a 8.63% increase, with the full-year FY2025 number at $719.0 million, up 8.63% from a year prior.
  • Revenue was $211.6 million for Q4 2025 at Supernus Pharmaceuticals, up from $192.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $211.6 million in Q4 2025 to a low of $130.9 million in Q1 2021.
  • A 5-year average of $161.8 million and a median of $161.7 million in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: soared 37.86% in 2021, then decreased 20.28% in 2023.
  • Supernus Pharmaceuticals' Revenue stood at $159.0 million in 2021, then increased by 5.2% to $167.3 million in 2022, then fell by 1.8% to $164.3 million in 2023, then increased by 5.99% to $174.2 million in 2024, then grew by 21.48% to $211.6 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Revenue are $211.6 million (Q4 2025), $192.1 million (Q3 2025), and $165.5 million (Q2 2025).